A number of other equities research analysts also recently issued reports on MDG1. Baader Bank set a €22.00 ($26.19) price target on MediGene and gave the stock a buy rating in a research report on Wednesday, April 4th. Oddo Bhf set a €13.00 ($15.48) price target on MediGene and gave the stock a neutral rating in a research report on Friday, March 23rd.
Shares of MDG1 stock opened at €16.34 ($19.45) on Monday. MediGene has a 12 month low of €8.53 ($10.15) and a 12 month high of €19.27 ($22.94).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.